Rolipram attenuates MK-801-induced deficits in latent inhibition - PubMed (original) (raw)
Rolipram attenuates MK-801-induced deficits in latent inhibition
Jennifer A Davis et al. Behav Neurosci. 2005 Apr.
Abstract
Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.
Copyright (c) 2005 APA, all rights reserved.
Similar articles
- Latent inhibition of cued fear conditioning: an NMDA receptor-dependent process that can be established in the presence of anisomycin.
Lewis MC, Gould TJ. Lewis MC, et al. Eur J Neurosci. 2004 Aug;20(3):818-26. doi: 10.1111/j.1460-9568.2004.03531.x. Eur J Neurosci. 2004. PMID: 15255992 - Signal transduction mechanisms within the entorhinal cortex that support latent inhibition of cued fear conditioning.
Lewis MC, Gould TJ. Lewis MC, et al. Neurobiol Learn Mem. 2007 Oct;88(3):359-68. doi: 10.1016/j.nlm.2007.04.011. Epub 2007 Jun 8. Neurobiol Learn Mem. 2007. PMID: 17560814 - Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM. Zhang HT, et al. Neuropsychopharmacology. 2000 Aug;23(2):198-204. doi: 10.1016/S0893-133X(00)00108-1. Neuropsychopharmacology. 2000. PMID: 10882846 - Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T, Mouri A, Murai R, Noda Y. Nabeshima T, et al. Ann N Y Acad Sci. 2006 Nov;1086:160-8. doi: 10.1196/annals.1377.003. Ann N Y Acad Sci. 2006. PMID: 17185514 Review. - Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity.
Kovacic P, Somanathan R. Kovacic P, et al. Oxid Med Cell Longev. 2010 Jan-Feb;3(1):13-22. doi: 10.4161/oxim.3.1.10028. Oxid Med Cell Longev. 2010. PMID: 20716924 Free PMC article. Review.
Cited by
- Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP.
Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, Houslay MD, Kanes SJ, Abel T. Kelly MP, et al. Neuropsychopharmacology. 2007 Mar;32(3):577-88. doi: 10.1038/sj.npp.1301099. Epub 2006 May 31. Neuropsychopharmacology. 2007. PMID: 16738544 Free PMC article. - Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.
Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Siuciak JA, et al. Psychopharmacology (Berl). 2008 Mar;197(1):115-26. doi: 10.1007/s00213-007-1014-6. Epub 2007 Dec 1. Psychopharmacology (Berl). 2008. PMID: 18060387 - The role of phosphodiesterases in schizophrenia : therapeutic implications.
Siuciak JA. Siuciak JA. CNS Drugs. 2008;22(12):983-93. doi: 10.2165/0023210-200822120-00002. CNS Drugs. 2008. PMID: 18998737 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources